Attendee search 

A full service investment banking and securities brokerage firm which serves the needs of both private and public companies worldwide, as well as individual and institutional investors.

We are committed to forging lasting partnerships with emerging growth companies and the investors who back them. Our simple approach is to provide customized financial solutions for virtually any need. A complete range of investment banking and brokerage services are available to our valued corporate and individual clients.

oronary Artery Disease (CAD) is the leading cause of death worldwide, accounting for over 7 Million deaths annually — more than any other disease category.

Premier Heart's Multifunction Cardiogram is the only non-invasive online diagnostic testing tool designed to assist physicians in quickly and accurately detecting heart diseases, including CAD ischemia.
When compared to traditional methods MCG has consistently been able to more accurately detect ischemia at earlier stages, enabling physicians to intervene and save lives.

The results from MCG have been validated in double-blind clinical studies where our system has demonstrated accuracy comparable to coronary angiography (90% overall sensitivity, 85% specificity).
This level of accuracy results from advanced techniques in signal processing and systems analysis combined with our unmatched clinical database which allows MCG to provide quantitative, evidence-based results to assist in reaching a diagnosis.

We invite you to review our clinical trial results, user endorsements and technical data. If you want to learn more about using MCG in your practice or would like more information about our technology please feel free to contact us.

YU School of Medicine is one of the nation’s preeminent academic institutions. For more than 150 years, we have trained thousands of physician-scientists who have helped to shape the course of medical history and enrich the lives of countless people. Through medical education, scientific research, and patient care, we continue to demonstrate our deep, abiding commitment to improving the human condition.

The percentage of NYU graduates who are members of medical school faculties is among the highest in the nation. For most of them, an invaluable part of that training was their service at Bellevue Hospital, one of the nation’s finest municipal hospitals, where NYU physicians have provided clinical and emergency care to
New York City’s poor and immigrant populations for more than a century.

As part of a “biomedical corridor” extending from 23rd to 34th Streets along Manhattan’s East River Drive, our institution is guided by the promise of “translational medicine,” in which scientific discoveries are urgently translated into innovative treatments for patients. To create an environment worthy of rapid medical advances, we are constructing new research and clinical facilities. These state-of-the-art facilities will serve as the home for our physician-scientists who are the intellectual foundation of the School. In addition, we are recruiting a new generation of scholars and teachers who have established national and international reputations. And we are admitting some of the nation’s best and brightest students, many of whom will become tomorrow’s leaders in the medical profession.

Your focus and ours is whether NYU is the right place to pursue your medical education. We hope that this website captures the spirit of the educational enterprise at NYU, as well as the experience of studying medicine in the heart of New York City.

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer.

The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma.

The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells.

The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors.

Immune is headquartered in the U.S., with its primary research and development facilities in Israel.

Life Science Nation (LSN) was founded by Dennis Ford, CEO, in 2012 to bring a better sales and marketing awareness to the life science community. LSN’s goal is to educate scientists in the basic skills required to brand, message, and market their companies.

Before LSN, Dennis was the CEO of a company that pioneered a system for uncovering global institutional investors and gauging their appetite regarding investing in hedge funds, private equity funds, and venture capital (VC) funds. The methodology used to capture and curate this valuable data was developed in part by a research team that would cold call and canvass these investors. The team would conduct a one-on-one interview with each investor that uncovered any current investment mandates they had. This allowed them to identify exactly where the capital was and specifically who had the mandate to deploy it.

After working with fundraisers in the alternative finance space for six years, Dennis wanted to bring his expertise to the life sciences and channel this fundraising experience toward the goal of moving science forward. Dennis knew from his experience in the alternatives field that many institutional investors and family offices were starting to withdraw capital from funds due to a decade of sub-par returns, initiating a trend of direct investment. This dovetailed with an accelerating trend of philanthropic investment and a desire among many investors to eradicate diseases affecting their family, friends or other groups that they have an affinity towards.

Identifying who has capital and is a fit for your company is the conundrum of the life science arena. The life science industry is poised at the entryway of a new golden age.  The one factor holding back the life science explosion is lack of capital. Dennis’s vision led him to believe that LSN could expedite the capital-raising problem by identifying active life science investors seeking emerging biotech and medtech companies and creating in-depth profiles that detail their specific preferences.  This would allow scientist-entrepreneurs to identify investors based on fit for their stage and sector, thus greatly enhancing the results of their outbound fundraising campaigns.

Dennis sought to create a match.com-like sourcing platform for the life sciences.  He knew that he needed not only current, accurate, and actionable information on both of the constituent groups who would use the platform, but also a home for the data he had started to gather on early stage life science investors.

The Roche Translational and Clinical Research Center (TCRC) is part of the Pharma Research and Early Development (pRED) organization, and will serve as the hub for pRED activities in North America, underscoring the center’s importance to pRED and Roche. The TCRC staff is comprised of highly experienced drug developers who are focused on early clinical development of Roche drug candidates. In addition to advancing Roche’s existing portfolio, the TCRC experts will aim to access external innovation by identifying collaborations ranging from very early discovery platforms through advanced stage molecules.

We build financial products so you can participate in the healthcare and life science economy. Companies, investors, consumers and entrepreneurs will have access to financial products to create and/or manage their financial exposure to healthcare and the life science sector.

Poliwogg's management team has extensive experience in finance, healthcare, foundations, government and investing. It combines that expertise with a passion for increasing and broadening investment in healthcare, the largest sector of the American economy.

In 2007, the university opened a 22,000 square foot Research Building that focuses on science and houses the Botulinum Research Center. The building, the first at UMass Dartmouth devoted entirely to research, strengthens an "Innovation Triangle" in southeastern Massachusetts that includes major research and development centers in New Bedford and Fall River.

This year marks 10 years of progress since Autism Speaks first opened its doors in 2005. As we move into our 11th year our goal is to significantly enhance autism services in every  community and push to get the groundbreaking ABLE Act , now the law of the land, implemented in all 50 states. Our dedicated field teams will be the ones heading this effort.

Thanks to the passion and generosity of our community, Autism Speaks has helped advance our understanding and treatment of autism in ways almost unimaginable ten years ago.